PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2014 | 10 | 1 |
Tytuł artykułu

Effect of puerarin on human choriocarcinoma cells

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Objective: To discuss the effect of puerarin on human choriocarcinoma cells. Methods: Survival rates under puerarin monotherapy, fluorouracil (5-FU) monotherapy and puerarin in combination with 5-FU were detected by MTT assay. Apoptotic morphology was observed with Hoechst 33258 staining. Apoptosis rates were detected with flow cytometry. Expressions of AKT, mechanistic target of rapamycin (mTOR), and P70S6K mRNAs and phosphorylated proteins were detected by RT-PCR and Western blot. Tumor-bearing mice were administered puerarin and puerarin+5-FU, and serum levels of β-human chorionic gonadotropin (β-HCG) were measured. Results: Proliferation inhibition and apoptosis rates of JEG-3 cells were positively correlated with puerarin concentration, which increased in the puerarin+5-FU group. Expression levels of AKT, mTOR, P70S6K mRNAs, and phosphorylated proteins decreased significantly after action of puerarin at different concentrations. With increasing puerarin concentration, expression of cleaved-caspase-3 in JEG-3 cells increased, whereas that of Bcl-2 decreased. Puerarin significantly inhibited tumor growth in choriocarcinoma-bearing SCID mice. Serum β-HCG levels were significantly lower than those of control group after administration. Magnitude of β-HCG decline was positively correlated with concentration. Conclusion: Puerarin+5-FU inhibited proliferation of JEG-3 choriocarcinoma cells and promoted their apoptosis, being associated with the mTOR signaling pathway.
Słowa kluczowe
Wydawca

Czasopismo
Rocznik
Tom
10
Numer
1
Opis fizyczny
Daty
otrzymano
2015-01-31
zaakceptowano
2015-03-19
online
2015-04-28
Twórcy
autor
  • Department of Pharmacy,
    Affiliated Hospital of Inner Mongolia Medical University, Hohhot
    010059, PR China
autor
  • Department of Pharmacy,
    Affiliated Hospital of Inner Mongolia Medical University, Hohhot
    010059, PR China
autor
  • Department of Pharmacy,
    Affiliated Hospital of Inner Mongolia Medical University, Hohhot
    010059, PR China
autor
  • Department of Pharmacy,
    Affiliated Hospital of Inner Mongolia Medical University, Hohhot
    010059, PR China
autor
  • Department of Scientific
    Research, Affiliated Hospital of Inner Mongolia Medical University,
    Hohhot 010059, PR China
autor
  • College of Mongolian Medicine, Inner Mongolia Medical
    University, Hohhot 010059, PR China
Bibliografia
  • [1] Abbasi N.Z., Zahur Z., Sheikh A.S., Khan A.A., Ahmed F.,Memon K.H., et al., Testicular choriocarcinoma: diagnosedon cervical lymph node biopsy, J. Pak. Med. Assoc., 2014, 63,1544-1546.
  • [2] Yazgan Y., Öncü K., Kaplan M., Tanoğlu A., Küçük I., ÖzarıH.O., et al., Upper gastrointestinal bleeding as an initialmanifestation of metastasis secondary to choriocarcinoma,Turk. J. Gastroenterol., 2014, 24, 565-567.[WoS]
  • [3] Chen Y., Qian H., Wang H., Zhang X., Fu M., Liang X., et al.,Ad-PUMA sensitizes drug-resistant choriocarcinoma cells tochemotherapeutic agents, Gynecol. Oncol., 2007, 107, 505-512.[WoS][Crossref]
  • [4] Kawamura K., Kawamura N., Okamoto N., Manabe M.,Suppression of choriocarcinoma invasion and metastasisfollowing blockade of BDNF/TrkB signaling, Cancer Med., 2014,2, 849-861.[WoS][Crossref]
  • [5] Sorbi F., Sisti G., Pieralli A., Di Tommaso M., Livi L., BuccolieroA.M., et al., Cervicoisthmic choriocarcinoma mimickingcesarean section scar ectopic pregnancy, J. Res. Med. Sci.,2014, 18, 914-917.
  • [6] Dach J., Jeffrey Dach, MD: The Transition to a Natural MedicinePractice, Altern. Ther. Health M., 2014, 20, 52-57.
  • [7] Ni Y., Zhuang H., Kokot S., A High Performance Liquid Chromatographyand Electrospray Ionization Mass SpectrometryMethod for the Analysis of the Natural Medicine, ForsythiaSuspensa, Anal. Lett., 2014, 47, 102-116.[WoS][Crossref]
  • [8] Niitsu T., Okamoto H., Iyo M., Behavioural and psychologicalsymptoms of dementia in an Alzheimer’s disease casesuccessfully treated with natural medicine: association withgonadotropins, Psychogeriatrics, 2013, 13, 124-127.[WoS][Crossref]
  • [9] Li H., Dong L., Liu Y., Wang G., Zhang L., Qiao Y., Comparisonof two approaches of intestinal absorption by puerarin, J.Pharmacol. Toxicol. Methods, 2014, 70, 6-11.[Crossref][WoS]
  • [10] Pignataro G., Capone D., Polichetti G., Vinciguerra A., GentileA., Di Renzo G., et al., Neuroprotective, immunosuppressantand antineoplastic properties of mTOR inhibitors: current andemerging therapeutic options, Curr. Opin. Pharmacol., 2011, 11,378-394.[Crossref][WoS]
  • [11] Gentzler R.D., Altman J.K., Platanias L.C., An overview of themTOR pathway as a target in cancer therapy, Expert Opin. Ther.Targets, 2012, 16, 481-489.[Crossref]
  • [12] Kim Y.J., Lee J., Song M.K., Han T., Ryu J.C., Valproic acidinhibits cell size and cell proliferation by AMPK-mediated mTORsignaling pathway in JEG-3 cells, BioChip J., 2013, 7, 267-277.[WoS][Crossref]
  • [13] Eren Y., Özata A., Determination of mutagenic and cytotoxiceffects of Limonium globuliferum aqueous extracts by Allium,Ames, and MTT tests, Rev. Bras. Farmacogn., 2014, 24, doi:10.1590/0102-695X20142413322.[WoS][Crossref]
  • [14] Morice L., Benaitreau D., Dieudonné M.N., Morvan C., SerazinV., de Mazancourt P., et al., Effets antiprolifératifs et proapoptotiquesdu bisphénol A dans les cellules trophoblastiqueshumaines JEG-3, Immuno-Anal. Biol. Spe., 2012, 27, 168-176.
  • [15] Xu J.T., Zhao X., Yaster M., Tao Y.X., Expression and distributionof mTOR, p70S6K, 4E-BP1, and their phosphorylatedcounterparts in rat dorsal root ganglion and spinal cord dorsalhorn, Brain Res., 2010, 1336, 46-57.[WoS]
  • [16] Lee D.Y., Li Y.S., Chang S.F., Zhou J., Ho H.M., Chiu J.J., et al.,Oscillatory flow-induced proliferation of osteoblast-like cellsis mediated by alpha vbeta3 and beta1 integrins throughsynergistic interactions of focal adhesion kinase and Shc withphosphatidylinositol 3-kinase and the Akt/mTOR/p70S6Kpathway, J. Biol. Chem., 2009, 285, 30-42.
  • [17] Zheng J.H., Lu J.Q., Cheng M.J., Xu C.J., [Lung metastasisof human choriocarcinoma in mice: establishment ofexperimental metastatic model and its biological characteristics],Zhonghua Fu Chan Ke Za Zhi, 2010, 45, 519-524.
  • [18] Sekine R., Hyodo M., Kojima M., Meguro Y., Suzuki A.,Yokoyama T., et al., Primary hepatic choriocarcinoma in a49-year-old man: report of a case, World J. Gastroenterol.,2014, 19, 9485-9489.[WoS]
  • [19] Froeling F.E., Seckl M.J., Gestational Trophoblastic Tumours: AnUpdate for 2014, Curr. Oncol. Rep., 2014, 16, 408.[Crossref]
  • [20] Berkowitz R.S., Goldstein D.P., Horowitz N.S. ManagementOptions of Gestational Trophoblastic Disease, Curr. Obstet.Gynecol. Rep., 2014, 3, 76-83.[Crossref]
  • [21] Cole L.A., The hCG Group: the Key Molecules in HumanEvolution, Human Life, and Human Death, Curr. Obstet.Gynecol. Rep., 2014, 3, 91-101.[Crossref]
  • [22] Strohl A.E., Lurain J.R., Clinical Epidemiology of GestationalTrophoblastic Disease, Curr. Obstet. Gynecol. Rep., 2014, 3,40-43.[Crossref]
  • [23] Horn L.C., Einenkel J., Hoehn A.K., Classification andMorphology of Gestational Trophoblastic Disease, Curr. Obstet.Gynecol. Rep., 2014, 3, 44-54.[Crossref]
  • [24] Nguyen N.M.P., Slim R., Genetics and Epigenetics of RecurrentHydatidiform Moles: Basic Science and Genetic Counselling,Curr. Obstet. Gynecol. Rep., 2014, 3, 55-64.[Crossref]
  • [25] Shi D., Tan Z., Lu R., Yang W., Zhang Y., MicroRNA-218 inhibitsthe proliferation of human choriocarcinoma JEG-3 cell line bytargeting Fbxw8, Biochem. Bioph. Res. Co., 2014, 450, doi:10.1016/j.bbrc.2014.06.094.[Crossref]
  • [26] Manguso F., Bennato R., Lombardi G., Viola A., Riccio E.,Picascia S., et al., P.15.6 DETERMINATION OF SERUM CORTISOLBY ECLIA UNDERSTIMATES SERUM CORTISOL SUPPRESSION INTHE PRESENCE OF PREDNISONE IN PATIENTS WITH UC. Digest,Liver Dis., 2014, 46, S112.
  • [27] Liu C., Chen T., Lin J., Chen H., Chen J., Lin S., et al., Evaluationof the performance of four methods for detection of hepatitisB surface antigen and their application for testing 116,455specimens, J. Virol. Methods, 2014, 196, 174-178.[WoS]
  • [28] Yang J., Sa M., Huang M., Yang J., Xiang Z., Liu B., et al., Thereference intervals for HE4, CA125 and ROMA in healthy femalewith electrochemiluminescence immunoassay, Clin. Biochem.,2013, 46, 1705-1708.[Crossref][WoS]
  • [29] Garrett L.D., Canine mast cell tumors: diagnosis, treatment,and prognosis, Vet. Med. Res. Rep., 2014, 2014, 49-58.[Crossref]
  • [30] Rasoulpour R.J., Terry C., LeBaron M.J., Stebbins K., Ellis-Hutchings R.G., Billington R., Mode-of-action and humanrelevance framework analysis for rat Leydig cell tumorsassociated with sulfoxaflor, Crit. Rev. Toxicol., 2014, 44, 25-44.[Crossref][WoS]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_1515_med-2015-0039
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.